AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Recognize income changes, expense spikes, or goal shifts as signals to reallocate resources and refresh your plan before issues arise.
18,671 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Investors are using margin loans to amplify gains, but rising leverage could trigger sharp moves. The latest margin d...
With American Express set to report on July 24, analysts say a durable franchise, disciplined capital returns, and a ...
Small-cap stocks are delivering the sharpest outperformance versus the S&P 500 in years, with a roughly 20% YTD g...
Moonshot AI unveils the Kimi K3 model, sparking a swift repricing in AI bets and sending chipmakers and tech names in...
Austin Niemiec returns to lead Rocket Pro as executives depart, signaling a strengthened wholesale channel amid a vol...
Headwinds have pressured Vornado, but two strategic catalysts could unlock meaningful upside. This guide breaks down ...
A trio of midstream dividend ETFs yielding more than 5% are delivering market-beating performance, offering both inco...
Palantir is navigating a mix of headwinds and catalysts as 2026 unfolds. Here are three grounded predictions palantir...
A new study finds AI chatbots misinterpret uncertainty terms, a misalignment that could influence personal-finance de...
Cactus (WHD) finishes 2025 with solid top-line growth and steadier margins. This report breaks down cactus (whd) 2025...
Block pivots on AI, slashing 40% of jobs as it refocuses on crypto tools and fintech services. This morning minute lo...